Bactericidal cationic peptides can also function as bacteriolysis-inducing agents mimicking beta-lactam antibiotics?; it is enigmatic why this concept is consistently disregarded

Medical Hypotheses

Volumn 62, Issue 3, 2004, Pages 367-374

  Ginsburg, Isaac ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA LACTAM ANTIBIOTIC; CATHEPSIN G; DEFENSIN; ELASTASE; ENDOTOXIN; HEPARIN; LACTOFERRIN; LIPOTEICHOIC ACID; LYSOZYME; NEUTROPHIL DERIVED PERMEABILITY INCREASING PEPTIDE; PEPTIDE; PEPTIDOGLYCAN; PHOSPHOLIPASE A2; PROTEINASE; PROTEINASE INHIBITOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; AUTOLYSIS; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DRUG CHOICE; DRUG INDICATION; DRUG MECHANISM; HUMAN; INTENSIVE CARE; MACROPHAGE ACTIVATION; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPTIC SHOCK;

EQUUS CABALLUS;

EID: 1642284891     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.017     Document Type: Article

References (82)

1. Gladstone GP, Abraham EP. Acquired immunity: the serological reactions of bacteria. In: Florey H, editor. General pathology. London: Lloyd-Luke (Medical Books); 1964. p. 860-79.
2. Fleming A. On the remarkable bactriolytic element found in tissues and secretion. Proc R Soc B 1922;93: 303-17.
3. Salton MRJ. The bacterial cell wall. Elsevier: Amsterdam; 1964.
4. Shockman GD, Daneo-Moor L, Kariyama R, Massidda O. Bacterial walls, peptidoglycan hydrolases, autolysins and autolysis. Microb Drug Resist 1996;2:95-8.
5. Ghuysen JM. Bacteriolytic enzymes in determination of wall structure and their role inn cell metabolism. Bact Rev 1968;32:425-64.
6. Glynn AA. The complement lysozyme sequence in immune bacteriolysis. Immunology 1969;16:463-71.
7. Ginsburg I. The biochemistry of bacteriolysis: facts, paradoxes and myths. Microbiol Sci 1988;5:137-42.
8. Ginsburg I. The role of bacteriolysis in the pathophystology of inflammation, infection and post-infectious sequelae. APMIS 2002;110:753-70.
9. Bichowski-Slominski L, Berger A, Kurtz J, Katchalski E. The antibacterial action of some basic amino acids copolymers. Arch Biochem Biophys 1956;65:400-13.
10. Skarness RC, Watson DW. Anti-microbial factors of normal tissues and fluids. Bact Rev 1957;21:273-94.
11. Odeberg H, Olson I. Antibacterial activity of cationic proteins from human granulocytes. J Clin Invest 1957;56: 1118-24.
12. Hirsch JG. The bactericidal action of histone. J Exp Med 1958;108:925-44.
13. Zeya HI, Spitznagel JK. Antibacterial and enzyme basic protein from leukocyte lysosomes, separation and identification. Science 1963;142:1085-7.
14. 2-independent microbicidal systems of phagocytes. Rev Infect Dis 1993;5:843-53.
15. Elsbach P. The bactericidal/permeability-increasing (BPI) in antibacterial defense. J Leuk Biol 1998;64:14-8.
16. Yeaman MR, Bayer AS. Anti microbial peptides from platelets. Drug Resist Updat 1999;2:116-26.
17. Ganz T, Lehrer RI. Antibiotic peptides from higher eukaryotes: biology and application. Mol Med Today 1999:292-7.
18. Levy O. The neutrophil-derived anti-infective molecules: bacterial/permeability-increasing protein. Antimicrob Agents Chemother 2000;44:2925-31.
19. Hancock REW, Scott MG. The role of anti microbial peptides in animal defenses. PNAS (USA) 2000;97: 8856-61.
20. Risso A. Leukocyte anti-microbial peptides: multifactorial effector molecules of innate immunity. J Leuk Biol 2000;68:783-92.
21. Chertov O, Yang De, Zack Howard OM, Oppenheim JJ. Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immun Rev 2000;177: 68-78.
22. Levi O. Antimicrobial proteins and peptides of blood: templates for novel antimictrobial agents. Blood 2000;96: 2664-72.
23. Hancock REW. Cationic peptides: effectors in innate immunity and novel antimicrobials. The Lancet Infect Dis 2001;1:156-64.
24. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002;109:693-7.
25. Lehrer T, Ganz T. Cathelicidins: family of endogenous anti microbial peptides. Curr Opin hematol 2002;9:180-22.
26. Zasloff M. Anti-microbial peptides of multicellular organisms. Nature 2002;415:389-95.
27. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. The Lancet Infect Dis 2002;2:171-9.
28. Ginsburg I. Cationic polyelecrolytes: a new look at their roles as opsonins, as stimulators of the respiratory burst in leukocytes, in bacteriolysis and as modulators of immune-complex diseases. Inflammation 1987;11: 489-515.
29. Ginsburg I. Cationtc polyelectrolytes: potent opsonic agents which activate the respiratory burst in leukocytes. Free Rad Res Comms 1989;8:11-26.
30. Ginsburg I, Kohen R. Cell damage in inflammatory and infectious sites might involve a coordinated cross-talk among oxidants, microbial hemolysins and amphiphiles, cationic proteins, phospholipases, proteinases and cytokines. Free Rad Res 1995;22: 489-717.
31. Ginsburg I. Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins and cytokines be the main cause of tissue damage in infectious and inflammatory conditions? Med Hypothesis 1998;51: 337-46.
32. Lahav M, Ginsburg I. The effect of leukocyte hydrolases on bacteria X. The role played by leukocyte factors, cationic polyelectrolytes and by membrane-damaging factors in the lysis of Staphylococcus aureus: relation to chronic inflammatory processes. Inflammation 1977;2: 165-77.
33. Ginsburg I, Lahav M, Giesbrecht P. The effect of leukocyte hydrolases on bacteria XVI. Activation by leukocyte factors and cationic substances of autolytic wall enzymes in Staphytococcus aureus: modulation by anionic inflammatory exudates. Inflammation 1982;6:269-84.
34. Ginsburg I. Cationic peptides from leukocytes might kill bacteria by activating their autolytic enzymes causing bacteriolysis: why are publications proposing this concept never acknowledged? Blood 2001;97: 2530-1.
35. Bierbaum G, Sahl HG. Influence of the activity of autolytic acetylglucosaminidase of Staphylococcus simulans 22. FEMS Microbiol Lett 1998;58:223-8.
36. Shal HG. Bactericidal cationic peptides involved in bacterial antagonism and host defense. Microbiol Sci 1985;2: 212-7.
37. Wecke J, Lahav M, Ginsburg I, Giesbrecht P. Cell wall degradation of Staphylococcus aureus by lysozyme. Arch Microbiol 1982;131:116-23.
38. Cottagnoud P, Tomasz A. Triggering of pneumococcal autolysis by lysozyme. J Infect Dis 1993;167: 684-90.
39. Laible NJ, Germain GR. Bactericidal activity of human lysozyme, muramidase-inactive lysozyme, and cationic polypeptides against Streptococcus sanguis and streptococcus faecails: inhibition by chitin oligosaccharides. Infect Immun 1985;48:20-8.
40. During K, Porsch P, Mahn A, Brinkmann O, Gieffers W. The non-enzymatic microbicidal activity of lysozyme. FEBS Lett 1999;449:93-100.
41. Tomasz A. From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. Rev Infect Dis 1979;1: 434-67.
42. Shenep JL. Antibiotic-induced bacteriolysis: a therapeutic dilemma. Eur J Clin Microbiol 1986;5:1-12.
43. Holzheimer RG. The significance of endotoxin release in experimental and clinical sepsis in surgical patients-evidence for antibiotic-induced endotoxin release. Infection 1998;26:77-84.
44. Pereti P, Mazzei T. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of septic shock; a review. J Chemother 1998;10:427-48.
45. Holtje JV. From growth to autolysis. The murein hydrolases of E.Coli. Arch Microbiol 1995;164:243-54.
46. Johansen L, Labischinski H, Burghaus P, Giesbrecht P. Acetylation in different phases of growth of staphylococci and their relation to cell wall degradability by lysozyme. In: Hakenbeck R, Holtje JV, Labischinski H, editors. The target of penicillin. Berlin, New York: Walter de Gruyter & Co; 1983. p. 261-6.
47. Sela MN, Ginsburg I. The effect of leukocyte hydrolases on bacteria IX. The release of lipoteichoic acid from group A streptococci and from Streptococcus mutons by leukocyte extracts and by lysozyme: relation to tissue damage in inflammatory sites. Inflammation 1977;2: 151-64.
48. Demonti J, De Graev J. Release of endotoxic lipopolysaccharide by sensitive strains of Escherichia coli submitted to the bactericidal action of human serum. Med Microbiol Ilmmunol 1982;170:265-77.
49. Ferne M, Duchan Z, Rabinowitz-Bergner S, Sela MN, Ginsburg I. The effect of leukocyte hydrolases on bacteria XII. The release of lipopolysaccahride (LPS) from Salmolella typhi leukocyte extracts, lysozyme, inflammatory exudates and synovial fluid and the modulation by anionic and cationic polyelectrolytes of LPS release and the sensitization of erythrocytes. Inflammation 1978; 3:59-80.
50. Zhang H, Niesel DW, Peterson JW, Kimpel GR. Lipoprotein rerlease by bacteria: potential factor in bacterial pathogenesis. Infect Immun 1998;66:5196-201.
51. Ginsburg I, Lahav M. Lysis and biodegradation of microorganisms in infectious sites may involve cooperation between leukocyte and serum factors and bacterial wall autolysins: a working hypothesis. Eur J Clin Microbiol 1983; 2:186-91.
52. The Margaux Conference on Critical Illness: activation of the coagulation system in critical illness. Crit care Med 2000;28:S1-S137.
53. Bjerre A, Brusletto B, Mollnes TE, et al. Complement activation by purified Neissera mieningitis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS mutant. J Infect Dis 2002;185:220-8.
54. Opal SM, Cohen J. Clinical Gram-positive bacterial sepsis: does it fundamentally differ from Gram-negative bacterial sepsis? Crit Care Med 1999;27:1608-18.
55. Glauser MP. Pathophysiological basis of sepsis: considerations for future strategies of intervention. Crit Care Med 2000;28:S4-8.
56. Ginsburg I, Sela MN. The role leukocytes and their hydrolases in the persistence, degradation, and transport of bacterial constituents in tissues: relation to chronic inflammatory processes in staphylococcal, streptococcal and mycobacterial infections and in periodontal disease. CRC Crit Rev Microbiol 1976;4: 249-322.
57. Ginsburg I, Lahav M, Ne'eman N, Duchan Z, Chanes S, Sela MN. Interaction of leukocytes and their hydrolases with bacteria in vitro and in vivo: the modification of the bactericidal and bacteriolytic reactions by cationic and anionic macromolecular substances and by anti-inflammatory agents. Agents Actions 1976;6: 292-305.
58. Ginsburg I. Bacteriolysis is inhibited by hydrogen peroxide and by proteases. Agents Actions 1989;28:238-42.
59. Wecke J, Lahav M, Ginsburg I. Inhibition of wall autolysis of staphylococci by polyanethole sulfonate. Arch Microbiol 1986;144:110-5.
60. Wecke J, Kwa J, Lahav M, Ginsburg I, Giesbrecht P. Suppression of penicillin-induced bacteriolysis of staphylococci by some anticoagulants. J Antimicrobial Chemotherapy 1987;20:47-55.
61. Froidevaux C, Roger T, Martin C, Glauser M. Macrophage migration inhibitory factor and innate immune response to bacterial infections. Crit Care Med 2001;29: S13-5.
62. Richardson MA, Ramirez T, Russel NC, Moye LA. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med 1999;5:42-7.
63. Ginsburg I. Hypothesis: Is a failure to prevent bacteriolysis and the synergy among microbial and host-derived proinflammatory agonists the main contributory factors to the pathogenesis of post-infectious sequelae? Inflammation 2001;25:1-10.
64. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. The New Eng J Med 2003;348:138-50.
65. Ginsburg I. Multidrug strategies are necessary to inhibit the synergistic mechanism causing tissue damage and organ failure in post-infectious sequelae. Inflammopharmacology 1999;7:207-17.
66. Ginsburg I, Ward P, Varani J. Can we learn from the pathogenetic properties of group A hemolytic streptococci how tissues are injured and organs fail in post-infectious and inflammatory sequelae? FEMS Immunol Med Microbiol 1999;25:325-38.
67. Ginsburg I, Sadovnic M. Gamma globulin, Evan's blue, aprotinin, tetracycline and anti oxidants protect epithelial cells against damage induced by synergism among streptococcal hemolysins, oxidants and proteinases: releation to the prevention of post-streptococcal sequelae and septic shock. PFEMS Immunol Med Microbiol 1998;22: 247-56.
68. Vincent JL, Sun Q, Dubois MJ. Clincal trials of immunomodulatory therapies in severe sepsis and septic shock. CID 2002:1084-93.
69. Marshall JC. Clinical trials of mediator-directed therapy in sepsis: What have we learned? Intens Care Med 2000;26:S75-83.
70. Canepari P, Boaretti M. Lipoteichoic acid as a target for antimicrobial action. Microb Drug Resist 1996;21:85-9.
71. Easmon C. The protein C pathway. Crit care Med 2000; 28:S44-8.
72. Shimizu T, Tani T, Endo Y, Hanasawa K, Tsuchiya M, Kodama M. Elevation of plasma peptidoglycan and neutrophils activation during hemorrhage shock: plasma peptidoglycan reflects bacterial translocation and may affect neutrophil activation. Crit Care Med 2002;30: 77-82.
73. Cross AS, Opal SM, Bhattacharjee AK, et al. Immunotherapy of sepsis: flawed concept or faulty implementation? Vaccine 1999;17:S13-21.
74. Periti P. Current treatment of sepsis and endotoxemia. Expert Opin Pharmacother 2000;6:1203-7.
75. Vincent JL, Lopes Ferreira E. Evaluation of organ failure: we are making progress. Intens Care Med 2000;26: 1023-4.
76. van der Poll T. Immunotherapy of sepsis. The Lancet Infect Dis 2001;1:165-74.
77. Krishnagopalan S, Dellinger RP. Innovative therapies for sepsis. Bio Drugs 2001;15:645-54.
78. Llwelyn M, Cohen J. New insights into the pathogenesis and therapy of sepsis and septic shock. Curr Clin Top Infect Dis 2001;21:148-71.
79. Opal SM. Clinical impact of novel anticoagulation strategies in sepsis. Curr Opin Crit Care 2001;7:347-53.
80. Healy DP. New and emerging therapies for sepsis. Ann Pharmacother 2002;36:648-54.
81. Ginsburg I. Cationic polyelectrolytes from leukocytes might kill bacteria by activation their autolytic systems:emgmatically, the relevance of this phenomenon to post-infectious sequelae is disregarded. Intens Care Med 2002;28:1188.
82. Ginsburg I. The disregard syndrome: a menace to honest science? The Scientist 2001;15:51.